| 44.39 Data as of May 24 |  +0.04 / +0.09%Today’s Change | 31.48 Today|||52-Week Range 46.90 | +18.47% Year-to-Date |
| ABCO Posts Solid 4Q and FY2013 Earnings - Analyst Blog May 13 / Zacks.com |
| Previous close | 44.35 |
| Today’s open | 44.17 |
| Day’s range | 43.68 - 44.54 |
| Volume | 166,563 |
| Average volume (3 months) | 561,472 |
| Market cap | $2.2B |
| Dividend yield | -- |
| Earnings growth (last year) | -6.07% |
| Earnings growth (this year) | +2.50% |
| Earnings growth (next 5 years) | +7.41% |
| Revenue growth (last year) | -1.15% |
| P/E ratio | 21.2 |
| Price/Sales | 1.56 |
| Price/Book | 3.56 |
| Today’s change | Today’s % change | |
|---|---|---|
| ISISIsis Pharmaceuticals... | +0.34 | +1.65% |
| ICLRICON PLC | -0.02 | -0.06% |
| ABCOAdvisory Board Co | +0.19 | +0.38% |
| ALNYAlnylam Pharmaceutic... | +0.92 | +3.28% |
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | $0.72 |
| Annual revenue (last year) | $1.1B |
| Annual profit (last year) | $97.3M |
| Net profit margin | 8.99% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer James C. Foster |
Executive VP, Chief Financial & Accounting Officer Thomas F. Ackerman, CPA |
Corporate headquarters Wilmington, Massachusetts |
.
